Initiating Antiretroviral Therapy During HIV Infection
- 28 November 2001
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (20) , 2597-2599
- https://doi.org/10.1001/jama.286.20.2597
Abstract
Highly active antiretroviral therapy (HAART) has changed the landscape of human immunodeficiency virus (HIV) care in the developed world. Many patients with aKeywords
This publication has 16 references indexed in Scilit:
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001
- HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral LoadJAMA, 2001
- Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistenceAIDS, 2001
- When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA studyAIDS, 2001
- Predictors of optimal virological response to potent antiretroviral therapyAIDS, 1999
- Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitorAIDS, 1998
- Sex differences in HIV-1 viral load and progression to AIDSThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection.The Journal of Infectious Diseases, 1997
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996